Key result
Chronic ticagrelor treatment in patients 1 year post-ACS did not protect against endothelial ischemia-reperfusion injury compared to treatment discontinuation.
Why the study?
Experimental studies suggest ticagrelor may protect against ischemia-reperfusion injury, but patient data were lacking.
Does chronic ticagrelor treatment prevent endothelial ischemia-reperfusion injury in patients with a previous ACS?
Observational
Does chronic ticagrelor treatment prevent endothelial ischemia-reperfusion injury in patients with a previous ACS?
Chronic ticagrelor treatment does not protect against endothelial ischemia-reperfusion injury or improve basal endothelial function in patients 1 year after an ACS.
Answers are grounded in this paper and cite their sources.
Chronic ticagrelor does not protect against endothelial IR injury post-ACS; leaves open pleiotropic contributions to outcomes.
Background: Ticagrelor is a recommended P2Y 12 receptor inhibitor after acute coronary syndrome (ACS). Its superiority has been suggested to rely on pleiotropic effects beyond platelet inhibition. Experimental studies indicate that ticagrelor may protect from ischemia-reperfusion injury but no data are available from such studies on patients. This study aimed to determine if chronic ticagrelor treatment protects against endothelial ischemia-reperfusion injury in patients with a previous ACS. Methods: Patients with a previous ACS were studied with flow mediated dilatation of the left brachial artery to determine the degree of endothelial ischemia-reperfusion injury before and after discontinuation of ticagrelor treatment, which had been continuous since 1 year. Each patient underwent 3 identical examinations. The first examination (Visit A) was at the end of ticagrelor treatment and the following 2 (Visit B and C) were after cessation of this treatment with an interval of 2 to 4 weeks. Results: Ischemia and reperfusion induced significant impairment of endothelial function at all 3 occasions (absolute decline in flow mediated dilatation 3.0% ± 0.7 at Visit A ( P < 0.001), 1.9% ± 0.9 at Visit B ( P < 0.05) and 1.9% ± 0.4 at Visit C ( P < 0.0001)). However, there was no difference in the degree of endothelial ischemia-reperfusion injury or baseline endothelial function between the visits. Conclusion: Chronic ticagrelor treatment in patients 1 year after an ACS does not protect against endothelial ischaemia-reperfusion injury. Nor is it associated with better basal endothelial function compared to after discontinuation of treatment.
No takes yet. Share an insight, caveat, or question.
Verouhis et al. (2020) conducted an observational in Acute Coronary Syndrome. Ticagrelor vs. Discontinuation of ticagrelor was evaluated on Degree of endothelial ischemia-reperfusion injury (absolute decline in flow mediated dilatation). Chronic ticagrelor treatment in patients 1 year post-ACS did not protect against endothelial ischemia-reperfusion injury compared to treatment discontinuation.
Synapse has enriched 10 related papers. Consider them for comparative context: